Howard Pien - Idera Pharmaceuticals Director
| IDRADelisted Stock | USD 0.43 0.05 10.42% |
Director
Mr. Howard H. Pien is Director of the Company. Mr. Pien was the Chairman of the Board and Chief Executive Officer of Medarex, Inc, until it was acquired by Bristol Myers Squibb and Chairman of the Board and Chief Executive Officer of Chiron Corporationrationration, until it was acquired by Novartis. Mr. Pien was the President of Pharmaceuticals at SmithKline Beecham and the President of International of Glaxo Smith Kline. Early in his career, Mr. Pien served in roles at Abbott Laboratories and Merck Co since 2018.
| Age | 59 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 484 348 1600 |
| Web | https://www.iderapharma.com |
Howard Pien Latest Insider Activity
Tracking and analyzing the buying and selling activities of Howard Pien against Idera Pharmaceuticals stock is an integral part of due diligence when investing in Idera Pharmaceuticals. Howard Pien insider activity provides valuable insight into whether Idera Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Idera Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Idera Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Howard Pien over a year ago Acquisition by Howard Pien of 675 shares of Juno Therapeutics subject to Rule 16b-3 |
Idera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1519) % which means that it has lost $0.1519 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3232) %, meaning that it created substantial loss on money invested by shareholders. Idera Pharmaceuticals' management efficiency ratios could be used to measure how well Idera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 656 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Idera Pharmaceuticals has a current ratio of 5.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Idera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Idera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Idera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Idera to invest in growth at high rates of return. When we think about Idera Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Detlefsen | SunOpta | 52 | |
| Theron Gilliam | GMS Inc | 56 | |
| Joseph Swedish | CDW Corp | 66 | |
| Pablo Grattarola | BBB Foods | 51 | |
| Lynda Clarizio | CDW Corp | 57 | |
| Rose Lynch | Steven Madden | 68 | |
| Terence Leahy | National Vision Holdings | 59 | |
| Ronald Ross | GMS Inc | 66 | |
| David Tehle | National Vision Holdings | 61 | |
| Alejandro Davila | BBB Foods | 46 | |
| Brendan Springstubb | SunOpta | 32 | |
| Jay Amato | SunOpta | 54 | |
| Katrina Houde | SunOpta | 59 | |
| Heather Cianfrocco | National Vision Holdings | 45 | |
| Paul Finnegan | CDW Corp | 65 | |
| Ravi Sachdev | Steven Madden | 41 | |
| Shan Atkins | SunOpta | 59 | |
| Albert Bolles | SunOpta | 60 | |
| Virginia Albanese | CDW Corp | 51 | |
| David Smith | GMS Inc | 68 | |
| Leslie Keating | SunOpta | 57 | |
Management Performance
| Return On Equity | -0.32 | |||
| Return On Asset | -0.15 |
Idera Pharmaceuticals Leadership Team
Elected by the shareholders, the Idera Pharmaceuticals' board of directors comprises two types of representatives: Idera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Idera. The board's role is to monitor Idera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Idera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Idera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Howard Pien, Director | ||
| Carl MD, Chief Officer | ||
| MB ChB, Advisor | ||
| James Geraghty, Chairman of the Board | ||
| Joanna Horobin, Senior Vice President Chief Medical Officer | ||
| William Reardon, Lead Independent Director | ||
| III MBA, Adviser | ||
| Julian Baker, Executive Director of Market Devel. and Director | ||
| Mark Goldberg, Director | ||
| Vincent Milano, CEO and President and Director | ||
| Louis Arcudi, CFO, Senior Vice President - Operations, Treasurer, Secretary | ||
| Sudhir Agrawal, President CEO, Director | ||
| Robert Fletcher, Sr. VP of Bus. Devel. and Strategic Planning | ||
| Michael Dougherty, Director | ||
| Youssef Zein, Independent Vice Chairman of the Board | ||
| Robert Doody, VP of Investor Relations and Corporate Communications | ||
| John Taylor, CEO Director | ||
| Kelvin Neu, Director | ||
| Andy Jordan, Chief Officer | ||
| John Kirby, Principal Financial Officer and Accounting Officer | ||
| Cristina Csimma, Director | ||
| Carol Schafer, Director | ||
| Eve Slater, Independent Director | ||
| Bryant Lim, Senior Vice President General Counsel, Secretary | ||
| Maxine Gowen, Director | ||
| Shah MD, Medical Oncology | ||
| FRSC DPhil, Scientific Advisor | ||
| Daniel Salain, Chief Officer | ||
| John CPA, Chief Officer |
Idera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Idera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (354.22) % | |||
| Current Valuation | (8.7 M) | |||
| Shares Outstanding | 62.36 M | |||
| Shares Owned By Insiders | 29.55 % | |||
| Shares Owned By Institutions | 5.52 % | |||
| Number Of Shares Shorted | 414.67 K | |||
| Price To Earning | (4.69) X | |||
| Price To Book | 0.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Idera Stock
If you are still planning to invest in Idera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Idera Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |